3 Out-of-Favor Stocks Walking a Fine Line

Yahoo

26-05-2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
While market timing can be an extremely profitable strategy, it has burned many investors and requires rigorous analysis - something we specialize in at StockStory. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.
One-Month Return: -5.6%
Founded in 2000 with the idea that network security comes before endpoint security, Rapid7 (NASDAQ:RPD) provides software as a service that helps companies understand where they are exposed to cyber security risks, quickly detect breaches and respond to them.
Why Do We Pass on RPD?
Offerings struggled to generate meaningful interest as its average billings growth of 4.6% over the last year did not impress
Estimated sales growth of 2% for the next 12 months implies demand will slow from its three-year trend
Projected 2.4 percentage point decline in its free cash flow margin next year reflects the company's plans to increase its investments to defend its market position
At $22.88 per share, Rapid7 trades at 1.7x forward price-to-sales. If you're considering RPD for your portfolio, see our FREE research report to learn more.
One-Month Return: -5.2%
One of the largest homebuilding companies in the U.S., D.R. Horton (NYSE:DHI) builds a variety of new construction homes across multiple markets.
Why Does DHI Give Us Pause?
Product roadmap and go-to-market strategy need to be reconsidered as its backlog has averaged 19.4% declines over the past two years
Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
Shrinking returns on capital suggest that increasing competition is eating into the company's profitability
D.R. Horton is trading at $118.63 per share, or 9.2x forward P/E. Check out our free in-depth research report to learn more about why DHI doesn't pass our bar.
One-Month Return: -4%
With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.
Why Is TECH Not Exciting?
Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
Subscale operations are evident in its revenue base of $1.21 billion, meaning it has fewer distribution channels than its larger rivals
Free cash flow margin shrank by 8.2 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
Bio-Techne's stock price of $48.25 implies a valuation ratio of 22.5x forward P/E. Read our free research report to see why you should think twice about including TECH in your portfolio, it's free.
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free.